Ramirez Asset Management Inc. Acquires 8,100 Shares of AbbVie Inc. $ABBV

Ramirez Asset Management Inc. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 58.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,027 shares of the company's stock after acquiring an additional 8,100 shares during the quarter. Ramirez Asset Management Inc.'s holdings in AbbVie were worth $4,089,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA bought a new position in AbbVie during the second quarter worth $25,000. TD Capital Management LLC boosted its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after purchasing an additional 58 shares during the period. Abound Financial LLC bought a new position in AbbVie during the first quarter worth $30,000. Cypress Capital Management LLC WY bought a new position in AbbVie during the first quarter worth $35,000. Finally, Bear Mountain Capital Inc. boosted its position in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company's stock worth $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is owned by institutional investors.

Insider Activity at AbbVie

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on ABBV. UBS Group set a $251.00 price objective on shares of AbbVie in a research report on Friday, October 3rd. Daiwa Capital Markets raised AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 target price for the company in a report on Thursday, August 7th. Daiwa America raised AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 7th. Hsbc Global Res downgraded AbbVie from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 1st. Finally, Raymond James Financial reissued an "outperform" rating on shares of AbbVie in a report on Monday, August 25th. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $229.38.

AbbVie Stock Performance

AbbVie stock opened at $231.03 on Friday. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The business's 50-day moving average price is $214.12 and its two-hundred day moving average price is $196.58. The stock has a market cap of $408.13 billion, a PE ratio of 110.01, a P/E/G ratio of 1.35 and a beta of 0.51.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter in the prior year, the firm earned $2.65 EPS. The business's revenue was up 6.6% on a year-over-year basis. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be issued a $1.64 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 annualized dividend and a yield of 2.8%. AbbVie's dividend payout ratio is presently 312.38%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.